Ionis Pharmaceuticals IncNASDAQ:IONS
- LAST PRICE40.0400
- TODAY'S CHANGE (%)-0.8100 (-1.9829%)
- Bid / Lots40.0000/ 8
- Ask / Lots40.0600/ 2
- Open / Previous Close40.7600 / 40.8500
- Day Range
- 52 Week Range
- Volume306,791
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IONS |
|---|---|---|
| 09:32 ET | 52045 | 40.32 |
| 09:34 ET | 1300 | 40.6199 |
| 09:38 ET | 1986 | 40.53 |
| 09:39 ET | 1200 | 40.6314 |
| 09:41 ET | 2048 | 40.8 |
| 09:43 ET | 1000 | 40.8 |
| 09:45 ET | 3000 | 40.815 |
| 09:48 ET | 1900 | 40.81 |
| 09:50 ET | 722 | 40.87 |
| 09:52 ET | 2309 | 40.72 |
| 09:54 ET | 900 | 40.735 |
| 09:56 ET | 15052 | 40.58 |
| 09:57 ET | 4280 | 40.41 |
| 09:59 ET | 1700 | 40.36 |
| 10:01 ET | 13673 | 40.34 |
| 10:03 ET | 1450 | 40.32 |
| 10:06 ET | 2366 | 40.225 |
| 10:08 ET | 950 | 40.32 |
| 10:10 ET | 719 | 40.33 |
| 10:12 ET | 800 | 40.3 |
| 10:14 ET | 10345 | 40.2 |
| 10:15 ET | 5546 | 40.32 |
| 10:17 ET | 319 | 40.34 |
| 10:19 ET | 5002 | 40.2 |
| 10:21 ET | 1450 | 40.14 |
| 10:24 ET | 2099 | 40.24 |
| 10:26 ET | 300 | 40.27 |
| 10:28 ET | 2461 | 40.26 |
| 10:30 ET | 743 | 40.27 |
| 10:32 ET | 1800 | 40.27 |
| 10:33 ET | 1649 | 40.31 |
| 10:35 ET | 2200 | 40.32 |
| 10:37 ET | 1925 | 40.32 |
| 10:39 ET | 400 | 40.315 |
| 10:42 ET | 1963 | 40.27 |
| 10:44 ET | 879 | 40.24 |
| 10:46 ET | 1815 | 40.24 |
| 10:48 ET | 300 | 40.26 |
| 10:50 ET | 1789 | 40.18 |
| 10:51 ET | 900 | 40.165 |
| 10:53 ET | 3851 | 40.21 |
| 10:55 ET | 700 | 40.21 |
| 10:57 ET | 7582 | 40.13 |
| 11:00 ET | 4603 | 40.25 |
| 11:02 ET | 5802 | 40.22 |
| 11:04 ET | 2543 | 40.135 |
| 11:06 ET | 8568 | 40.03 |
| 11:08 ET | 11612 | 40.19 |
| 11:09 ET | 7924 | 40.1 |
| 11:11 ET | 3493 | 40.065 |
| 11:13 ET | 3681 | 40.075 |
| 11:15 ET | 3498 | 40.09 |
| 11:18 ET | 2400 | 40.11 |
| 11:20 ET | 2180 | 40.06 |
| 11:22 ET | 400 | 40.12 |
| 11:24 ET | 1200 | 40.115 |
| 11:26 ET | 700 | 40.11 |
| 11:27 ET | 1000 | 40.03 |
| 11:29 ET | 2617 | 40.04 |
Sep 26, 2024
DJ Ionis Pharmaceuticals Price Target Maintained With a $70.00/Share by RBC Capital, from 10:33AM ET on Thursday Sep 26, 2024 by Dow Jones
10:33AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 12, 2024
DJ The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update, from 1:01PM ET on Thursday Sep 12, 2024 by Dow Jones
1:01PM ET on Thursday Sep 12, 2024 by Dow JonesDJ The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ, from 7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 10, 2024
DJ Ionis Pharmaceuticals Down Over 10%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk, from 11:52AM ET on Tuesday Sep 10, 2024 by Dow Jones
11:52AM ET on Tuesday Sep 10, 2024 by Dow JonesDJ S&P 500 Futures Steady In Premarket Trading; Oracle, Sonoco Products Lead, from 7:30AM ET on Tuesday Sep 10, 2024 by Dow Jones
7:30AM ET on Tuesday Sep 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ionis Pharmaceuticals Inc | 6.6B | -15.8x | --- |
Halozyme Therapeutics Inc | 7.9B | 22.3x | --- |
Tempus AI Inc | 7.6B | -6.7x | --- |
Intra-Cellular Therapies Inc | 8.0B | -85.3x | --- |
Ultragenyx Pharmaceutical Inc | 5.4B | -7.7x | --- |
Ascendis Pharma A/S | 6.9B | -15.1x | --- |
Company Information
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Contact Information
- Headquarters
- 2855 Gazelle CourtCARLSBAD, CA, United States 92010
- Phone
- 760-931-9200
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Loscalzo
- Chief Executive Officer, Director
- Brett Monia
- Chief Financial Officer, Executive Vice President - Finance
- Elizabeth Hougen
- Executive Vice President, Chief Scientific Officer
- C. Frank Bennett
- Executive Vice President, Chief Business Officer
- Joseph Baroldi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.6B |
|---|---|
Revenue (TTM) | $813.5M |
Shares Outstanding | 157.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $-2.53 |
Book Value | $2.68 |
P/E Ratio | -15.8x |
Price/Sales (TTM) | 8.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -44.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
